Each year, an estimated 1.28 million people are diagnosed with a blood cancer, accounting for roughly 6% of all new cancer cases worldwide1.
These challenging disorders are genetically complex, often harboring a range of somatic mutations. In recent years, studies have uncovered a multitude of disease-associated genetic alterations that are fueling precision-oncology research and progressing hope for a better future in managing these diseases.
Traditional molecular testing involves iterative single-analyte approaches, complex workflows, all of which results in variable, often lengthy, turnaround times.
Next-generation sequencing (NGS) has revolutionized the study of hematologic malignancies by streamlining genetic profiling. NGS allows for efficient, simultaneous assessment of multiple genetic biomarkers with a single assay. Advancements in NGS automation enable results to now be available in as fast as 1-2 days.
Watch a brief video to see how the Ion Torrent Genexus System can deliver rapid results with minimal user intervention for myeloid samples.
Deepen your understanding of hematological malignancies with an unmatched offering of NGS testing solutions and capabilities. We offer a range of NGS assays for applications across a spectrum of disease research areas. Each assay is provided as part of a complete solution on our trusted NGS platforms, the Ion GeneStudio S5 System and the Ion Torrent Genexus System.
Integrated analysis software streamlines reporting and facilitates the interpretation of results. Unmatched workflow automation simplifies the testing process, enabling any laboratory to adopt NGS testing—including those without prior experience and expertise.
Our customers and collaborators are making incredible research advancements, disrupting traditional paradigms, and bringing forth new insights and approaches for understanding hematologic malignancies. Our NGS technology has been embraced by some of the top minds in the world to address the most pressing challenges is these disease research areas.
Implementing NGS for the Study of Lymphoid Malignancies
Gerard Frigola, MD
Hematopathologist
Hospital Clinic, IDIBAPS,
University of Barcelona
AMP 2023 Workshop On-Demand: NGS for Myeloid Malignancy Analysis
Cecilia Yeung, MD
Professor, Translational Science and Therapeutics Division
Medical Director, Fred Hutch Clinical Testing Labs
Fred Hutchinson Cancer Center
Utility of NGS
in Lymphoid
Malignancies
Dr. Michael Krigstein
Consultant Haematologist
MBBS(Hons) FRACP FRCPA MCncrSc
SydPath, St Vincent’s Hospital
Lymphoma Molecular Characterization - Assessing the Journey to Answers
Dr. Marianne Grantham
Barts Health NHS Trust
Advances in Immune Repertoire Sequencing for the Study of Lymphoid Neoplasm
Dr. John DeCoteau
Professor of Pathology & Laboratory Medicine, Medical Director, Advanced Diagnostic Research Laboratory, University of Saskatchewan
How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms
Dr. Bevan Tandon
Director of Hematopathology and Molecular Pathology,
Pathline Labs
Molecular Analysis in the Diagnosis and Prognosis of Hematological Malignancies
Gerard Frigola, MD
Hematopathologist
Hospital Clinic, IDIBAPS,
University of Barcelona
Sung H et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21660
For Research Use Only. Not for use in diagnostic procedures.
We've detected your location to be Japan.
Sorry, you cannot access this website. The content on www.oncomine.com is only intended for healthcare professionals. Formore information on our research solutions, please visit ThermoFisher.com
このウェブサイトは、日本国内の医療関係者の方への情報提供を目的としており、一般の方に対する情報提供を目的としたものではないことをご了承ください。研究用製品の情報はThermoFisher.comよりご覧ください。